InvestSMART

Rhythm Biosciences Limited (ASX: RHY) - Announcements

- Current share price for RHY : $0.087

ASX company news and announcements for Rhythm Biosciences Limited (RHY) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Rhythm Biosciences Limited (RHY) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Rhythm Biosciences Limited (RHY), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Rhythm Biosciences Limited (RHY)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$31 Rights Issue Investor Presentation 30 Jul 2021 11:12AM $0.950 $0.087 fallen by 90.84%
$31 Appendix 4C - quarterly 30 Jul 2021 10:40AM $0.940 $0.087 fallen by 90.74%
$31 Proposed issue of securities - RHY 30 Jul 2021 10:06AM $0.970 $0.087 fallen by 91.03%
$31 Non renouneable rights issue prospectus 30 Jul 2021 10:06AM $0.970 $0.087 fallen by 91.03%
$31 Rights issue to raise approximately $4.3 million 30 Jul 2021 10:03AM $0.970 $0.087 fallen by 91.03%
$31 Trading Halt 28 Jul 2021 8:27AM $0.970 $0.087 fallen by 91.03%
$31 Proposed issue of securities - RHY 27 Jul 2021 9:20AM $0.975 $0.087 fallen by 91.08%
$31 Notification regarding unquoted securities - RHY 26 Jul 2021 5:44PM $0.975 $0.087 fallen by 91.08%
$31 Notification regarding unquoted securities - RHY 26 Jul 2021 5:34PM $0.975 $0.087 fallen by 91.08%
$31 Final Director's Interest Notice 15 Jul 2021 8:19AM $0.850 $0.087 fallen by 89.76%
$31 Rhythm Establishes US Entity To Drive US Expansion Strategy 15 Jul 2021 8:13AM $0.850 $0.087 fallen by 89.76%
$31 Rhythm to Present at MST Access Investor Conference 17 Jun 2021 9:55AM $0.950 $0.087 fallen by 90.84%
$31 RHY adds Sonic Clinical Services to ColoSTAT Clinical Trial 16 Jun 2021 8:51AM $0.980 $0.087 fallen by 91.12%
$31 FY22 Strategic Update 18 May 2021 9:21AM $0.960 $0.087 fallen by 90.94%
$31 Rhythm Betters ColoSTAT Results 6 May 2021 9:29AM $0.865 $0.087 fallen by 89.94%
$31 Appendix 4C - quarterly 27 Apr 2021 9:19AM $1.120 $0.087 fallen by 92.23%
$31 Appendix 2A and Cleansing Notice 20 Apr 2021 4:52PM $1.145 $0.087 fallen by 92.40%
$31 Rhythm Extends ColoSTAT Clinical Trial to Western Australia 13 Apr 2021 9:11AM $1.195 $0.087 fallen by 92.72%
$31 Rhythm Retains ISO13485 Certification 31 Mar 2021 9:12AM $1.100 $0.087 fallen by 92.09%
$31 Study 6 Successfully Concluded - Exceptional Results 16 Mar 2021 9:22AM $1.500 $0.087 fallen by 94.20%
$31 Appendix 4D and Half Yearly Report and Accounts 25 Feb 2021 8:56AM $1.450 $0.087 fallen by 94%
$31 Rhythm Expands ColoSTAT Clinical Trial To Tenth Site 11 Feb 2021 9:06AM $1.555 $0.087 fallen by 94.41%
$31 Appendix 2A and Cleansing Notice 5 Feb 2021 2:49PM $1.320 $0.087 fallen by 93.41%
$31 Rhythm Top 20 Shareholder Update 29 Jan 2021 3:50PM $1.165 $0.087 fallen by 92.53%
$31 Appendix 4C - quarterly 28 Jan 2021 9:43AM $1.365 $0.087 fallen by 93.63%

476 - 500 of 645 results

Page 20 of 26

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.